The Latest Pharma Jobs, News and Events

The contact lenses – built for a modern and active lifestyle – help reduce exposure to bright light indoors and outdoors, including filtering blue light¨ and blocking UV rays that can impact eye comfort and vision.+‡ ii,iii,iv,v,vi

"Receiving this prestigious designation for ACUVUE OASYS with Transitions alongside other game-changing inventions that are improving the way we live in today's 'always on' world, is a major achievement for our company," said Ashley McEvoy, Executive Vice President and Worldwide Chairman, Medical Devices, Johnson & Johnson. "This ACUVUE innovation was born out of deep research into consumer lifestyle needs, and it took more than a decade to combine the revolutionary light-adaptive technology with these advanced contact lenses. The result are lenses that deliver a first-of-its-kind benefit, going beyond vision correction to be as nimble as consumers are in their everyday lives." 

The two-week reusable contact lens, which will be marketed by Johnson & Johnson Vision Care, Inc., continuously adapts from clear to dark and back, helping eyes adjust to changing light better than they would on their own. ACUVUE OASYS with Transitions begin to darken as soon as they're exposed to UV or HEV light, with Transitions Light Intelligent Technology enabling the lenses to become dark in 45 seconds – and fade back from dark to clear within 90 seconds when going from outdoors to indoors.v At full activation, the lenses block up to 70 percent of visible light.v The revolutionary contact lens experience is designed to offer the highest level of UV protection available in contact lenses and are the only contact lenses that provide 100% protection against UVB rays.+‡v,vii

ACUVUE OASYS with Transitions was developed through a strategic partnership between Johnson & Johnson Vision Care, Inc. and Transitions Optical Limited– combining the strengths and expertise of each company.

The contact lenses received 510(k) clearance for the attenuation of bright light from the U.S. Food and Drug Administration in April of this year, and was issued a medical device license by Health Canada in October of this year. They are expected to launch in the U.S., Canada and other select markets in the first half of 2019.